Role of induction chemotherapy in resectable N2 non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 2, Issue 5 SUPPL.1, 2007, Pages

  De Marinis, Filippo ^a,b,c   Tedesco, Beatrice ^a   Treggiari, Stefano ^a   De Santis, Stefano ^a   Cipri, Antonio ^a   Belli, Raffaele ^a   Condò, Silvia ^a   Ariganello, Ottavio ^a   Di Molfetta, Michele ^a   Migliorino, Maria Rita ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b FoRO (Oncological Research Foundation)   (Italy)

^c NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; VINDESINE; DEOXYCYTIDINE; DRUG DERIVATIVE; TAXOID; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONFIDENCE INTERVAL; HUMAN; LUNG NON SMALL CELL CANCER; MORTALITY; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; ADJUVANT THERAPY; CONTROLLED CLINICAL TRIAL; LUNG TUMOR; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; HUMANS; LUNG NEOPLASMS; NEOADJUVANT THERAPY; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; TAXOIDS; VINBLASTINE;

EID: 34250327969     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01.JTO.0000268639.48450.a4     Document Type: Conference Paper

References (25)

1. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000;18:2981-2989.
2. Basaki K, Abe Y, Aoki M, et al. Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume. Int J Radiat Oncol Biol Phys. 2006 Feb 1;64:449-454. Epub 2005 Oct 13.
3. Postoperative radiotherapy for non-small-cell lung cancer. Cochrane Database Syst Rev 2005;2:CD002142.
4. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.
5. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153-158.
6. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994;86:673-680.
7. Rosell R, Gomez-Codina J, Camps C, et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999;26:7-14.
8. Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998;21:1-6.
9. Nagai K, Tsuchiya R, Mori T, et al. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg 2003;125:254-260.
10. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002;20:247-253.
11. Berghmans T, Paesmans M, Meert AP, et al. Survival improvement in resectable non-small-cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 2005;49:13-23.
12. Van Zandwijk N, Smit EF, Kramer GW, et al. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol 2000;18:2658-2664.
13. Manegold C, Biesma B, Smit H, et al. Docetaxel and cisplatin as induction chemotherapy in stage IIIA N2 non-small-cell lung cancer (NSCLC): an EORTC phase II trial (08984) (Abstract). J Clin Oncol 2004;22:14S.
14. O'Brien ME, Splinter T, Smit EF, et al. Carboplatin and paclitaxel (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: an EORTC phase II study (EORTC 08958). Eur J Cancer 2003;39:1416-1422.
15. Van Schil P, Van Meerbeeck J, Kramer G, et al. Morbidity and mortality in the surgery arm of EORTC 08941 trial. Eur Respir J 2005;26:192-197.
16. Betticher DC, Hsu Schmitz SF, Totsch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003;21:1752-1759.
17. Migliorino MR, De Marinis F, Nelli F, et al. A 3-week schedule of gemcitabine plus cisplatin as induction chemotherapy for Stage III non-small-cell lung cancer. Lung Cancer 2002;35:319-327.
18. De Marinis F, Nelli F, Migliorino MR, et al. Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy-proven Stage IIIA(N2) nonsmall cell lung carcinoma: a Phase II multicenter study. Cancer 2003;98:1707-1715.
19. Leon L, Cueva-Banuelos JF, Huidobro G, et al. Gemcitabine, cisplatin and vinorelbine as induction chemotherapy followed by radical therapy in stage III non-small-cell lung cancer: a multicentre study of galician-lung-cancer-group. Lung Cancer 2003;40:215-220.
20. Ramnath N, Sommers E, Robinson L, et al. Phase II study of neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small-cell lung cancer. Chest 2005;128:3467-3474.
21. Pezzetta E, Stupp R, Zouhair A, et al. Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC. Eur J Cardiothorac Surg 2005;27:1092-1098.
22. Johnstone DW, Byhardt RW, Ettinger D, Scott, CB. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2002;54:365-369.
23. Albain KS, Swann RS, Rusch VR, et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small-cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309) (Abstract). J Clin Oncol 2005;23:16S.
24. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699.
25. Felip E, Stahel RA, Pavlidis N. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol 2005;16(Suppl 1):i28-i29.